Migraine Highlights From 2021 AHS Virtual Scientific Meeting

Brian M. Grosberg, MD


June 25, 2021

Key studies on migraine treatment presented at the American Headache Society's 63rd Annual Virtual Scientific Meeting included results from trials of two emerging preventive therapies.

Dr Brian Grosberg, of the University of Connecticut School of Medicine, reviews late-phase trial data demonstrating the efficacy of the oral CGRP antagonists atogepant and rimegepant for migraine prevention. He also discusses the findings from three different analyses that looked at the so-called "wear-off" phenomenon reported by a small number of users of biologic agents.

Dr Grosberg also reports on a summary of data from the CaMEO survey indicating that oral preventive therapies for migraine are greatly underutilized despite high interest among patients. He reviews results from the OUTCOME study, which identifies patient groups that are most likely to hesitate to seek migraine care. He explains key takeaways from a survey of obstetricians-gynecologists that assessed their comfort level with managing migraine in new or expecting mothers.

Finally, Dr Grosberg shares results from a new patient satisfaction survey that reveals how patients viewed telehealth measures for migraine care accessed during the COVID-19 pandemic.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.